AAV gene therapy (target 2) (Sarepta Therapeutics/StrideBio)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAAV gene therapy (target 2) (Sarepta Therapeutics/StrideBio)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionCNS modulators
TargetsUpdating
Therapy Area/IndicationsCentral Nervous System DiseasesMuscular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSarepta Therapeutics IncStridebio Inc
Active IndicationsN/A
Inactive IndicationsCentral Nervous System DiseasesMuscular Diseases

Other Information

ATC CodeN/A
Related LinksN/A